United States Food and Drug Administration, USA
Dr. Xi Yang joined the United States Food and Drug Administration (FDA) in 2009 working with Dr. William Salminen in the Division of Systems Biology at the National Center for Toxicological Research (NCTR). Her primary research focus is in improving drug safety by identifying new biomarkers of liver injury and their qualification, human genetic polymorphisms and smoking related human disease. At NCTR, Dr. Yang designed an innovative method for collecting, processing, and analyzing urinary microRNAs and found that urinary microRNAs may be superior to traditional biomarkers in predicting drug-induced liver injury. Prior to her work at NCTR, she obtained a Ph.D. degree in Genetics from Pennsylvania State University.